top of page
  • Twitter

Our Publications

Peer-reviewed research output from members of the Urological Malignancies Programme.

Disease overview 

Stewart GD, Klatte T, Cosmai L, Bex A, Lamb BW, Moch H, Sala E, Siva S, Porta C, Gallieni M. The multispeciality approach to the management of localised kidney cancer. Lancet. 2022 Aug 13;400(10351):523-534. doi: 10.1016/S0140-6736(22)01059-5. Epub 2022 Jul 19. PMID: 35868329. 

Translational science 

Patel SA, Hirosue S, Rodrigues P, Vojtasova E, Richardson EK, Ge J, Syafruddin SE, Speed A, Papachristou EK, Baker D, Clarke D, Purvis S, Wesolowski L, Dyas A, Castillon L, Caraffini V, Bihary D, Yong C, Harrison DJ, Stewart GD, Machiela MJ, Purdue MP, Chanock SJ, Warren AY, Samarajiwa SA, Carroll JS, Vanharanta S. The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer. Nature. 2022 Jun;606(7916):999-1006. doi: 10.1038/s41586-022-04809-8. Epub 2022 Jun 8. 

Young MD, Mitchell TJ, Custers L, Margaritis T, Morales-Rodriguez F, Kwakwa K, Khabirova E, Kildisiute G, Oliver TRW, de Krijger RR, van den Heuvel-Eibrink MM, Comitani F, Piapi A, Bugallo-Blanco E, Thevanesan C, Burke C, Prigmore E, Ambridge K, Roberts K, Braga FAV, Coorens THH, Del Valle I, Wilbrey-Clark A, Mamanova L, Stewart GD, Gnanapragasam VJ, Rampling D, Sebire N, Coleman N, Hook L, Warren A, Haniffa M, Kool M, Pfister SM, Achermann JC, He X, Barker RA, Shlien A, Bayraktar OA, Teichmann SA, Holstege FC, Meyer KB, Drost J, Straathof K, Behjati S. Single cell derived mRNA signals across human kidney tumors. Nat Commun. 2021 Jun 23;12(1):3896. doi: 10.1038/s41467-021-23949-5. PMID: 34162837; PMCID: PMC8222373.


Coorens THH, Farndon SJ, Mitchell TJ, Jain N, Lee S, Hubank M, Sebire N, Anderson J, Behjati S. Lineage-Independent Tumors in Bilateral Neuroblastoma. N Engl J Med. 2020 Nov 5;383(19):1860-1865. doi: 10.1056/NEJMoa2000962. PMID: 33211929; PMCID: PMC7611571. 

Sciacovelli M, Dugourd A, Jimenez LV, Yang M, Nikitopoulou E, Costa ASH, Tronci L, Caraffini V, Rodrigues P, Schmidt C, Ryan DG, Young T, Zecchini VR, Rossi SH, Massie C, Lohoff C, Masid M, Hatzimanikatis V, Kuppe C, Von Kriegsheim A, Kramann R, Gnanapragasam V, Warren AY, Stewart GD, Erez A, Vanharanta S, Saez-Rodriguez J, Frezza C. Dynamic partitioning of branched-chain amino acids-derived nitrogen supports renal cancer progression. Nat Commun. 2022 Dec 20;13(1):7830. doi: 10.1038/s41467-022-35036-4

Valcarcel-Jimenez L, Rogerson C, Yong C, Schmidt C, Yang M, Cremades-Rodelgo M, Harle V, Offord V, Wong K, Mora A, Speed A, Caraffini V, Tran MGB, Maher ER, Stewart GD, Vanharanta S, Adams DJ, Frezza C. HIRA loss transforms FH-deficient cells. Sci Adv. 2022 Oct 21;8(42):eabq8297. doi: 10.1126/sciadv.abq8297. Epub 2022 Oct 21. PMID: 36269833; PMCID: PMC9586478. 

Cancer screening 

Dennison RA, Taylor LC, Morris S, Boscott RA, Harrison H, Moorthie SA, Rossi SH, Stewart GD, Usher-Smith JA. Public Preferences for Determining Eligibility for Screening in Risk-Stratified Cancer Screening Programs: A Discrete Choice Experiment. Med Decis Making. 2023 Apr;43(3):374-386. doi: 10.1177/0272989X231155790. Epub 2023 Feb 14. PMID: 36786399; PMCID: PMC10021112. 

Harrison H, Wood A, Pennells L, Rossi SH, Callister M, Cartledge J, Stewart GD, Usher-Smith JA. Estimating the Effectiveness of Kidney Cancer Screening Within Lung Cancer Screening Programmes: A Validation in UK Biobank. Eur Urol Oncol. 2023 Mar 30:S2588-9311(23)00066-4. doi: 10.1016/j.euo.2023.02.012. Epub ahead of print. PMID: 37003861. 

Usher-Smith JA, Godoy A, Burge SW, Burbidge S, Cartledge J, Crosbie PAJ, Eckert C, Farquhar F, Hammond D, Hancock N, Iball GR, Kimuli M, Masson G, Neal RD, Rogerson S, Rossi SH, Sala E, Smith A, Sharp SJ, Simmonds I, Wallace T, Ward M, Callister MEJ, Stewart GD. The Yorkshire Kidney Screening Trial (YKST): protocol for a feasibility study of adding non-contrast abdominal CT scanning to screen for kidney cancer and other abdominal pathology within a trial of community-based CT screening for lung cancer. BMJ Open. 2022 Sep 20;12(9):e063018. doi: 10.1136/bmjopen-2022-063018. PMID: 36127097; PMCID: PMC9490622. 

Harrison H, Li N, Saunders CL, Rossi SH, Dennis J, Griffin SJ, Stewart GD, Usher-Smith JA. The current state of genetic risk models for the development of kidney cancer: a review and validation. BJU Int. 2022 Nov;130(5):550-561. doi: 10.1111/bju.15752. Epub 2022 May 7. PMID: 35460182; PMCID: PMC9790357. 

Harvey-Kelly LLW, Harrison H, Rossi SH, Griffin SJ, Stewart GD, Usher-Smith JA. Public attitudes towards screening for kidney cancer: an online survey. BMC Urol. 2020 Oct 28;20(1):170. doi: 10.1186/s12894-020-00724-0. PMID: 33115457; PMCID: PMC7592501. 

Usher-Smith JA, Harvey-Kelly LLW, Rossi SH, Harrison H, Griffin SJ, Stewart GD. Acceptability and potential impact on uptake of using different risk stratification approaches to determine eligibility for screening: A population-based survey. Health Expect. 2021 Apr;24(2):341-351. doi: 10.1111/hex.13175. Epub 2020 Dec 2. PMID: 33264472; PMCID: PMC8077132.


Harrison H, Pennells L, Wood A, Rossi SH, Stewart GD, Griffin SJ, Usher-Smith JA. Validation and public health modelling of risk prediction models for kidney cancer using the UK Biobank. BJU Int. 2022 Apr;129(4):498-511. doi: 10.1111/bju.15598. Epub 2021 Oct 7. PMID: 34538014. 

Early detection 

Rossi SH, Newsham I, Pita S, Brennan K, Park G, Smith CG, Lach RP, Mitchell T, Huang J, Babbage A, Warren AY, Leppert JT, Stewart GD, Gevaert O, Massie CE, Samarajiwa SA. Accurate detection of benign and malignant renal tumor subtypes with MethylBoostER: An epigenetic marker-driven learning framework. Sci Adv. 2022 Sep 30;8(39):eabn9828. doi: 10.1126/sciadv.abn9828. Epub 2022 Sep 28. PMID: 36170366; PMCID: PMC9519038. 

Gnanapragasam VJ, Greenberg D, Burnet N. Urinary symptoms and prostate cancer-the misconception that may be preventing earlier presentation and better survival outcomes. BMC Med. 2022 Aug 4;20(1):264. doi: 10.1186/s12916-022-02453-7. PMID: 35922801; PMCID: PMC9351095. 

Harrison H, Usher-Smith JA, Li L, Roberts L, Lin Z, Thompson RE, Rossi SH, Stewart GD, Walter FM, Griffin S, Zhou Y. Risk prediction models for symptomatic patients with bladder and kidney cancer: a systematic review. Br J Gen Pract. 2021 Dec 31;72(714):e11-e18. doi: 10.3399/BJGP.2021.0319. PMID: 34844922; PMCID: PMC8714528. 

Flitcroft JG, Verheyen J, Vemulkar T, Welbourne EN, Rossi SH, Welsh SJ, Cowburn RP, Stewart GD. Early detection of kidney cancer using urinary proteins: a truly non-invasive strategy. BJU Int. 2022 Mar;129(3):290-303. doi: 10.1111/bju.15601. Epub 2021 Nov 3. PMID: 34570419. 

Novel devices 

Gnanapragasam VJ, Leonard K, Sut M, Ilie C, Ord J, Roux J, Prieto MCH, Warren A, Tamer P. Multicentre clinical evaluation of the safety and performance of a simple transperineal access system for prostate biopsies for suspected prostate cancer: The CAMbridge PROstate Biopsy DevicE (CamPROBE) study. J Clin Urol. 2020 Sep;13(5):364-370. doi: 10.1177/2051415820932773. Epub 2020 Jun 12. PMID: 33072331; PMCID: PMC7521793. 

Advanced cancer imaging 

Ursprung S, Woitek R, McLean MA, Priest AN, Crispin-Ortuzar M, Brodie CR, Gill AB, Gehrung M, Beer L, Riddick ACP, Field-Rayner J, Grist JT, Deen SS, Riemer F, Kaggie JD, Zaccagna F, Duarte JAG, Locke MJ, Frary A, Aho TF, Armitage JN, Casey R, Mendichovszky IA, Welsh SJ, Barrett T, Graves MJ, Eisen T, Mitchell TJ, Warren AY, Brindle KM, Sala E, Stewart GD, Gallagher FA. Hyperpolarized 13C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma-A Proof of Principle Study. Cancers (Basel). 2022 Jan 11;14(2):335. doi: 10.3390/cancers14020335. PMID: 35053497; PMCID: PMC8773685. 

Sushentsev N, Barrett T, Warren AY, Gnanapragasam VJ. How and when should radiologists report T-staging on MRI in patients with prostate cancer? BJU Int. 2022 Oct;130(4):434-436. doi: 10.1111/bju.15824. Epub 2022 Jul 11. PMID: 35696280. 

Sushentsev N, Moreira Da Silva N, Yeung M, Barrett T, Sala E, Roberts M, Rundo L. Comparative performance of fully-automated and semi-automated artificial intelligence methods for the detection of clinically significant prostate cancer on MRI: a systematic review. Insights Imaging. 2022 Mar 28;13(1):59. doi: 10.1186/s13244-022-01199-3. PMID: 35347462; PMCID: PMC8960511. 

Sushentsev N, Kaggie JD, Slough RA, Carmo B, Barrett T. Reproducibility of magnetic resonance fingerprinting-based T1 mapping of the healthy prostate at 1.5 and 3.0 T: A proof-of-concept study. PLoS One. 2021 Jan 29;16(1):e0245970. doi: 10.1371/journal.pone.0245970. PMID: 33513165; PMCID: PMC7846281.


Prediction and prognostication of outcome 

Sushentsev N, Rundo L, Abrego L, Li Z, Nazarenko T, Warren AY, Gnanapragasam VJ, Sala E, Zaikin A, Barrett T, Blyuss O. Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance. Eur Radiol. 2023 Feb 7. doi: 10.1007/s00330-023-09438-x. Epub ahead of print. PMID: 36749370. 

Cancer follow-up and surveillence 

Oza B, Eisen T, Frangou E, Stewart GD, Bex A, Ritchie AWS, Kaplan R, Smith B, Davis ID, Stockler MR, Albiges L, Escudier B, Larkin J, Joniau S, Hancock B, Hermann GG, Bellmunt J, Parmar MKB, Royston P, Meade A. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. J Clin Oncol. 2022 Jun 1;40(16):1772-1782. doi: 10.1200/JCO.21.01090. Epub 2022 Feb 25. PMID: 35213214; PMCID: PMC9148696. 

Harrison H, Stewart GD, Usher-Smith JA. Patient experience of follow-up after surgery for kidney cancer: a focus group study. BJU Int. 2023 Feb 1. doi: 10.1111/bju.15982. Epub ahead of print. PMID: 36726216. 

Sushentsev N, Barrett T. The role of artificial intelligence in MRI-driven active surveillance in prostate cancer. Nat Rev Urol. 2022 Aug;19(8):510. doi: 10.1038/s41585-022-00619-9. PMID: 35715704. 

Usher-Smith JA, Stewart GD. Predicting cancer outcomes after resection of high-risk RCC. Nat Rev Urol. 2022 May;19(5):257-258. doi: 10.1038/s41585-022-00568-3. PMID: 35064250. 

Usher-Smith JA, Li L, Roberts L, Harrison H, Rossi SH, Sharp SJ, Coupland C, Hippisley-Cox J, Griffin SJ, Klatte T, Stewart GD. Risk models for recurrence and survival after kidney cancer: a systematic review. BJU Int. 2022 Nov;130(5):562-579. doi: 10.1111/bju.15673. Epub 2022 Jan 11. PMID: 34914159. 

Sushentsev N, Rundo L, Blyuss O, Nazarenko T, Suvorov A, Gnanapragasam VJ, Sala E, Barrett T. Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance. Eur Radiol. 2022 Jan;32(1):680-689. doi: 10.1007/s00330-021-08151-x. Epub 2021 Jul 13. PMID: 34255161; PMCID: PMC8660717. 

Sushentsev N, Rundo L, Blyuss O, Gnanapragasam VJ, Sala E, Barrett T. MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance. Sci Rep. 2021 Jun 21;11(1):12917. doi: 10.1038/s41598-021-92341-6. PMID: 34155265; PMCID: PMC8217549. 

Gnanapragasam VJ, Barrett T, Pacey S, Warren A. Does modern active surveillance offer an opportunity for new therapeutic strategies in early prostate cancer? BJU Int. 2021 Jun;127(6):628-629. doi: 10.1111/bju.15409. Epub 2021 Apr 16. PMID: 33774889. 

Neoadjuvant trials 

Stewart GD, Welsh SJ, Ursprung S, Gallagher FA, Jones JO, Shields J, Smith CG, Mitchell TJ, Warren AY, Bex A, Boleti E, Carruthers J, Eisen T, Fife K, Hamid A, Laird A, Leung S, Malik J, Mendichovszky IA, Mumtaz F, Oades G, Priest AN, Riddick ACP, Venugopal B, Welsh M, Riddle K, Hopcroft LEM; NAXIVA Trial Group; Jones RJ. A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). Br J Cancer. 2022 Oct;127(6):1051-1060. doi: 10.1038/s41416-022-01883-7. Epub 2022 Jun 23. PMID: 35739300; PMCID: PMC9470559. 

Klatte T, Welsh SJ, Riddick ACP, Karam JA, Stewart GD. Tyrosine kinase inhibitor treatment for renal cell carcinoma with inferior vena cava tumour thrombus: a quantitative summary. BJU Int. 2023 Jan 13. doi: 10.1111/bju.15966. Epub ahead of print. PMID: 36638048. 

Ursprung S, Mossop H, Gallagher FA, Sala E, Skells R, Sipple JAN, Mitchell TJ, Chhabra A, Fife K, Matakidou A, Young G, Walker A, Thomas MG, Ortuzar MC, Sullivan M, Protheroe A, Oades G, Venugopal B, Warren AY, Stone J, Eisen T, Wason J, Welsh SJ, Stewart GD. The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol. BMC Cancer. 2021 Nov 18;21(1):1238. doi: 10.1186/s12885-021-08965-4. PMID: 34794412; PMCID: PMC8600815. 

Welsh SJ, Thompson N, Warren A, Priest AN, Barrett T, Ursprung S, Gallagher FA, Zaccagna F, Stewart GD, Fife KM, Matakidou A, Machin AJ, Qian W, Ingleson V, Mullin J, Riddick ACP, Armitage JN, Connolly S, Eisen TGQ. Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib. BJU Int. 2022 Aug;130(2):244-253. doi: 10.1111/bju.15600. Epub 2021 Nov 2. PMID: 34549873. 

Adjuvant trials 

Eisen T, Frangou E, Oza B, Ritchie AWS, Smith B, Kaplan R, Davis ID, Stockler MR, Albiges L, Escudier B, Larkin J, Bex A, Joniau S, Hancock B, Hermann GG, Bellmunt J, Hodgkinson E, Stewart GD, Barber J, Brown J, McMenemin R, Nathan P, Pickering LM, Parmar MKB, Meade A. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. J Clin Oncol. 2020 Dec 1;38(34):4064-4075. doi: 10.1200/JCO.20.01800. Epub 2020 Oct 14. PMID: 33052759; PMCID: PMC7768344. 

Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, Powles T, Stewart GD, Albiges L, Bex A, Choueiri TK, Davis ID, Eisen T, Fielding A, Harrison D, McWhirter A, Mulhere S, Nathan P, Rini B, Ritchie A, Scovell S, Shakeshaft C, Stockler MR, Thorogood N, Parmar MKB, Larkin J, Meade A. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemp Clin Trials. 2021 Sep;108:106482. doi: 10.1016/j.cct.2021.106482. Epub 2021 Sep 16. PMID: 34538402; PMCID: PMC8520913. 

Meade A, Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, Powles T, Stewart GD, Albiges L, Bex A, Choueiri TK, Davis ID, Eisen T, Fielding A, Harrison DJ, McWhirter A, Mulhere S, Nathan P, Rini B, Ritchie A, Scovell S, Shakeshaft C, Stockler MR, Thorogood N, Larkin J, Parmar MKB. RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. Contemp Clin Trials. 2021 Sep;108:106481. doi: 10.1016/j.cct.2021.106481. Epub 2021 Sep 16. PMID: 34538401. 

bottom of page